Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.45 |
| ▸ | RARG | P13631 | 6/20 | 0.42 |
| ▸ | RARA | P10276 | 5/20 | 0.42 |
| ▸ | RARB | P10826 | 5/20 | 0.42 |
| ▸ | HTR1A | P08908 | 6/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | BCL9 | O00512 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18529800 | 0.92 | PAK4 (0.40) | PAK4NAMPTPAK1RARGRARA | |
| SCHEMBL19066902 | 0.88 | PAK4 (0.48) | PAK4NAMPTPAK1RARGRARA | |
| SCHEMBL18529760 | 0.87 | HTR1A (0.44) | HTR1AADRA1ADRD2NPC1L1 | |
| SCHEMBL19082515 | 0.87 | PAK4 (0.47) | PAK4NAMPTPAK1RARGRARA | |
| SCHEMBL19066899 | 0.82 | BCL9 (0.52) | PAK4NAMPTPAK1RARGRARA | |
| SCHEMBL19066868 | 0.81 | PAK4 (0.48) | PAK4NAMPTPAK1HTR1AHDAC1 | |
| SCHEMBL16379647 | 0.81 | PAK4 (0.63) | PAK4NAMPTPAK1HDAC2HDAC1 | |
| SCHEMBL18542169 | 0.81 | PAK4 (0.46) | PAK4NAMPTPAK1HDAC2HDAC1 | |
| SCHEMBL18529797 | 0.80 | PAK4 (0.42) | PAK4NAMPTPAK1HTR1AADRA1A | |
| SCHEMBL18152291 | 0.79 | BCL9 (0.47) | RARGRARARARBSCN9ABCL9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858347-B2 | Multicyclic compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858347-B2 | Multicyclic compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2019-01-17 | — | — | US | disclosed |
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2019-01-17 | — | — | US | disclosed |
| WO-2017117447-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017117447-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | MALT1, BCL9, BCL6 | PAK4 1828/4885NAMPT 3853/4885PAK1 2595/4885 |
| US-10858347-B2 | Multicyclic compounds and uses thereof | MALT1, BCL9, BCL6 | PAK4 1828/4885NAMPT 3853/4885PAK1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.